マントル細胞リンパ腫の世界市場

マントル細胞リンパ腫の世界市場は2030年までに37億米ドルに達する

2024年に25億米ドルと推定されるマントル細胞リンパ腫の世界市場は、分析期間2024-2030年にCAGR 6.8%で成長し、2030年には37億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである臨床検査診断は、CAGR 8.3%を記録し、分析期間終了時には19億米ドルに達すると予測されます。画像検査診断セグメントの成長率は、分析期間中CAGR 5.0％と推定されます。

米国市場は6億6,870万米ドルと推定、中国はCAGR11.0％で成長予測

米国のマントル細胞リンパ腫市場は、2024年に6億6,870万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億6,980万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.3%と6.7%と予測されています。欧州では、ドイツがCAGR 4.5%で成長すると予測されています。

世界のマントル細胞リンパ腫市場- 主要動向と促進要因のまとめ

マントル細胞リンパ腫ががん領域の臨床・調査で注目される理由とは？

非ホジキンリンパ腫の中でも希少で侵攻性の高いマントル細胞リンパ腫（MCL）は、その複雑な生物学的特徴、長期予後の悪さ、効果的な治療戦略の必要性から、世界の腫瘍学コミュニティからの注目が高まっています。非ホジキンリンパ腫全体の約6～8％を占めるMCLは、リンパ節の「マントル領域」のB細胞から発生し、t（11;14）染色体転座によるサイクリンD1の過剰発現が特徴です。多くの低悪性度リンパ腫とは異なり、MCLはしばしば侵攻的な臨床経過をとり、初回治療後も再発を繰り返しながら急速に進行します。このため、MCLは研究や治療法の革新にとって優先順位の高い疾患とみなされています。従来の化学療法や幹細胞移植では寛解の持続性に限界があるため、臨床医や研究者は早期発見戦略や標的療法の開発にますます力を注いでいます。また、この疾患の不均一性と患者間の治療効果のばらつきは、個別化医療とバイオマーカー主導のアプローチの重要性を強調しています。さらに、血液専門医の意識の高まり、診断ツールの改善、分子プロファイリングへのアクセスの増加は、より正確な分類とタイムリーな介入に寄与しています。世界のがん負担が増加し続け、精密腫瘍学がより利用しやすくなるにつれ、MCLは、より優れた治療パラダイムと長期的な管理選択肢が緊急に必要とされる疾患として、正当なスポットライトを浴びています。

新たな治療法と薬剤の承認は、MCLの治療状況をどのように変えているのでしょうか？

近年、ターゲット療法、免疫療法、次世代低分子の出現により、MCLの治療状況は大きく変化しています。初回治療では、R-CHOPやhyper-CVADなどの化学療法併用レジメンに続いて、適格患者には自家幹細胞移植が行われることが多いが、新規薬剤の承認により、再発または難治性の症例に新たな選択肢が提供されつつあります。イブルチニブ、アカラブルチニブ、ザヌブルチニブなどのブルトン型チロシンキナーゼ（BTK）阻害剤は、MCL細胞の生存に重要なB細胞受容体のシグナル伝達経路を阻害する能力により、二次治療の中心的存在となっています。これらの経口療法は、高い奏効率と管理可能な毒性プロファイルを示し、地域および学術的環境の両方において治療アルゴリズムに変化をもたらしています。BTK阻害剤に加え、venetoclaxのようなBCL-2阻害剤やレナリドマイドのような免疫調節薬の使用が、より深く持続的な寛解に寄与しています。この分野ではCAR-T細胞療法も有望視されており、ブレクスカブタジンオートロイセルが再発または難治性のMCLに対して承認を受け、個別化免疫療法の大きなマイルストーンとなりました。相乗効果をもたらす可能性のある二重特異性抗体や併用レジメンの調査も進行中です。臨床試験で有望な結果が出続けていることから、MCL治療のパラダイムは、化学療法に依存したものから、よりターゲットを絞った患者中心のアプローチへと進化しつつあり、これまで選択肢が限られていた患者にとって希望が広がっています。

MCLの管理において、診断、患者層別化、臨床モニタリングはどのような役割を果たすのか？

MCLは侵攻性が強く、臨床経過も様々であるため、正確でタイムリーな診断が重要です。免疫表現型分類、細胞遺伝学的解析、および分子プロファイリングは、医師がMCLの診断を確定し、組織学的検査で類似して見える他のサブタイプのB細胞リンパ腫と鑑別することを可能にする重要なツールです。免疫組織化学的検査によるサイクリンD1過剰発現の検出や蛍光in situハイブリダイゼーション（FISH）によるt（11;14）転座の同定は、依然として診断の特徴です。診断にとどまらず、マントル細胞リンパ腫International Prognostic Index（MIPI）のような予後予測ツールは、患者をリスクカテゴリーに層別化し、治療決定の指針となり、全生存期間を予測するのに役立ちます。次世代シーケンサーのような高感度技術を用いた微小残存病変（MRD）モニタリングは、臨床症状が現れる前に治療効果を評価し、再発を予測するために採用されるようになってきています。PET-CT検査などの画像診断法は、病期分類と治療効果の評価に依然として不可欠です。さらに、遺伝子プロファイリングにより、MCLの変異の状況をより深く理解することが可能となり、特定の治療法に対する耐性を予測するマーカーが明らかになり、個別化治療戦略の道が開かれつつあります。このような診断・モニタリングツールが臨床診療に組み込まれるようになると、治療の精度が向上するだけでなく、早期介入やオーダーメイドの治療調整を通じて患者の転帰も改善されるようになります。このような精密診断へのシフトは、MCL患者が疾患の適切な段階で最も効果的な治療を受けられるようにする上で極めて重要です。

世界のマントル細胞リンパ腫市場の成長を促進する要因は何か？

世界のマントル細胞リンパ腫市場の成長は、疾患に対する意識の高まり、血液悪性腫瘍の罹患率の増加、標的療法の出現、ヘルスケアアクセスの拡大など、さまざまな要因が重なり合うことによってもたらされます。世界のがん罹患率の増加や診断精度の向上は、特にこの疾患が多くみられる高齢化社会におけるMCL症例の増加に寄与しています。バイオ医薬品企業がBTK阻害剤、BCL-2拮抗剤、細胞療法の開発に多額の投資を行い、患者に新たな希望をもたらしていることから、医薬品の技術革新が重要な推進力となっています。FDAやEMAなどの規制機関は、ファストトラックやオーファンドラッグ指定を通じて画期的な治療法の承認プロセスを迅速化し、新薬の市場参入を加速させています。また、標的治療薬や免疫療法の臨床試験での成功は、既存企業や新興バイオテクノロジー企業による投資やパイプラインの拡充を促しています。さらに、新興市場における臨床インフラやがん治療センターの拡大により、先進的な治療や診断へのアクセスが増加しており、需要をさらに促進しています。プレシジョンメディシンやコンパニオンダイアグノスティックスの受け入れ拡大も、より個別化された治療レジメンを可能にし、個々の患者との出会いの価値を高め、長期的な疾患管理を強化しています。主要市場における好意的な償還政策と保険適用範囲の拡大は、高コストの治療法をより利用しやすくし、収益の成長を促進しています。これらの要因が相まって、市場力学はダイナミックかつ急速な発展を遂げ、より広範ながん治療分野における重要な注目分野となっています。

セグメント

診断タイプ（ラボ検査、画像検査、骨髄生検、その他の診断タイプ）、治療（診断、治療）、エンドユーザー（病院＆クリニック、外来手術センター、その他のエンドユーザー）

調査対象企業の例

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Bristol-Myers Squibb Company
• Celgene Corporation（BMS）
• Eli Lilly and Company
• F.？Hoffmann-La Roche Ltd.
• Gilead Sciences（Kite Pharma）
• GlaxoSmithKline plc（GSK）
• Incyte Corporation
• Janssen Pharmaceuticals（J&J）
• Merck & Co., Inc.
• Novartis AG
• Nurix Therapeutics Inc.
• Takeda Pharmaceutical Company Ltd.
• TG Therapeutics Inc.
• Verastem Oncology
• Zebra Biologics（Precision BioSciences）

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Mantle Cell Lymphoma Market to Reach US$3.7 Billion by 2030

The global market for Mantle Cell Lymphoma estimated at US$2.5 Billion in the year 2024, is expected to reach US$3.7 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Laboratory Exams Diagnosis, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Imaging Tests Diagnosis segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$668.7 Million While China is Forecast to Grow at 11.0% CAGR

The Mantle Cell Lymphoma market in the U.S. is estimated at US$668.7 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$769.8 Million by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.3% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Mantle Cell Lymphoma Market - Key Trends & Drivers Summarized

Why Is Mantle Cell Lymphoma Garnering Increased Clinical and Research Attention in Oncology?

Mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin’s lymphoma, is drawing increasing attention from the global oncology community due to its complex biology, poor long-term prognosis, and the critical need for effective treatment strategies. Representing approximately 6 to 8 percent of all non-Hodgkin lymphoma cases, MCL arises from B-cells in the “mantle zone” of lymph nodes and is characterized by the overexpression of cyclin D1 due to the t(11;14) chromosomal translocation. Unlike many indolent lymphomas, MCL often follows an aggressive clinical course, progressing rapidly with frequent relapses after initial therapy. This has led to MCL being considered a high-priority condition for research and therapeutic innovation. Clinicians and researchers are increasingly focusing on early detection strategies and the development of targeted therapies, as conventional chemotherapy and stem cell transplants offer limited durability in remission. The disease’s heterogeneity and the variation in treatment response among patients also emphasize the importance of personalized medicine and biomarker-led approaches. Additionally, the growing awareness among hematologists, improved diagnostic tools, and increasing access to molecular profiling are contributing to more accurate classifications and timely interventions. As the global cancer burden continues to rise and precision oncology becomes more accessible, MCL is receiving the spotlight it warrants as a disease that urgently requires better treatment paradigms and long-term management options.

How Are Emerging Therapies and Drug Approvals Transforming the Treatment Landscape for MCL?

Recent years have seen a significant transformation in the treatment landscape for mantle cell lymphoma, largely driven by the emergence of targeted therapies, immunotherapies, and next-generation small molecules. While initial treatment often involves combination chemotherapy regimens such as R-CHOP or hyper-CVAD followed by autologous stem cell transplantation in eligible patients, the approval of novel agents is offering new options for relapsed or refractory cases. Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib have become central to second-line treatment due to their ability to interfere with B-cell receptor signaling pathways critical to MCL cell survival. These oral therapies have demonstrated high response rates and manageable toxicity profiles, which has shifted treatment algorithms in both community and academic settings. In addition to BTK inhibitors, the incorporation of BCL-2 inhibitors like venetoclax and the use of immunomodulatory drugs such as lenalidomide are contributing to deeper and more durable remissions. The field is also exploring the promise of CAR-T cell therapy, with brexucabtagene autoleucel receiving approval for relapsed or refractory MCL, marking a major milestone in personalized immunotherapy. Research is ongoing into bispecific antibodies and combination regimens that may provide synergistic benefits. As clinical trials continue to yield promising results, the MCL treatment paradigm is evolving from a reliance on chemotherapy toward a more targeted, patient-centric approach, expanding hope for patients who previously had limited options.

What Role Do Diagnostics, Patient Stratification, and Clinical Monitoring Play in Managing MCL?

Accurate and timely diagnosis is critical in the management of mantle cell lymphoma due to its aggressive nature and variable clinical course. Immunophenotyping, cytogenetic analysis, and molecular profiling are key tools that enable physicians to confirm MCL diagnosis and differentiate it from other subtypes of B-cell lymphomas, which may appear similar under histological examination. The detection of cyclin D1 overexpression through immunohistochemistry or the identification of the t(11;14) translocation via fluorescence in situ hybridization (FISH) remains a diagnostic hallmark. Beyond diagnosis, prognostic tools such as the Mantle Cell Lymphoma International Prognostic Index (MIPI) help stratify patients into risk categories, guiding treatment decisions and predicting overall survival. Minimal residual disease (MRD) monitoring using highly sensitive techniques like next-generation sequencing is increasingly being adopted to assess treatment efficacy and anticipate relapse before clinical symptoms emerge. Imaging modalities such as PET-CT scans remain essential for staging and evaluating treatment response. Furthermore, genetic profiling is allowing for deeper insights into the mutational landscape of MCL, revealing markers that may predict resistance to specific therapies and opening avenues for personalized treatment strategies. As these diagnostic and monitoring tools become more integrated into clinical practice, they are not only improving treatment precision but also enhancing patient outcomes through early intervention and tailored therapy adjustments. This shift toward precision diagnostics is crucial in ensuring that patients with MCL receive the most effective therapies at the right stage of their disease.

What Factors Are Driving Growth in the Global Mantle Cell Lymphoma Market?

The growth in the global mantle cell lymphoma market is driven by a confluence of factors including rising disease awareness, increasing incidence of hematologic malignancies, the emergence of targeted therapies, and expanding healthcare access. The growing burden of cancer globally and improvements in diagnostic accuracy have contributed to a rise in identified MCL cases, particularly in aging populations where the disease is more prevalent. Pharmaceutical innovation is a key driver, as biopharmaceutical companies invest heavily in the development of BTK inhibitors, BCL-2 antagonists, and cellular therapies that offer new hope for patients. Regulatory agencies such as the FDA and EMA are expediting the approval process for breakthrough treatments through fast-track and orphan drug designations, accelerating market entry for novel drugs. The success of targeted therapies and immunotherapies in clinical trials is also encouraging more investment and pipeline expansion from both established players and emerging biotech firms. Additionally, the expansion of clinical infrastructure and cancer care centers in emerging markets is increasing access to advanced treatments and diagnostics, further fueling demand. Growing acceptance of precision medicine and companion diagnostics is also enabling more personalized treatment regimens, increasing the value of each patient encounter and enhancing long-term disease management. Favorable reimbursement policies and expanded insurance coverage in key markets are making high-cost therapies more accessible, thereby driving revenue growth. Together, these factors are creating a dynamic and rapidly evolving market for mantle cell lymphoma treatment, positioning it as a significant focus area in the broader oncology therapeutics sector.

SCOPE OF STUDY:

The report analyzes the Mantle Cell Lymphoma market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Diagnosis Type (Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy, Other Diagnosis Types); Treatment (Diagnosis Treatment, Therapy Treatment); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca plc
• Bayer AG
• BeiGene Ltd.
• Bristol-Myers Squibb Company
• Celgene Corporation (BMS)
• Eli Lilly and Company
• F.?Hoffmann-La Roche Ltd.
• Gilead Sciences (Kite Pharma)
• GlaxoSmithKline plc (GSK)
• Incyte Corporation
• Janssen Pharmaceuticals (J&J)
• Merck & Co., Inc.
• Novartis AG
• Nurix Therapeutics Inc.
• Takeda Pharmaceutical Company Ltd.
• TG Therapeutics Inc.
• Verastem Oncology
• Zebra Biologics (Precision BioSciences)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Mantle Cell Lymphoma - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Incidence of Rare Hematologic Cancers Throws the Spotlight on Mantle Cell Lymphoma as a High-Unmet-Need Oncology Subtype
  • Increased Use of Molecular Diagnostics and Immunophenotyping Propels Early and Accurate Detection of MCL
  • Here's the Story: Advancements in Targeted Therapies and Precision Medicine Strengthen the Business Case for MCL Drug Development
  • Expansion of BTK Inhibitors and Novel Small Molecules Drives Transformation in MCL Treatment Paradigms
  • Here's How CAR-T and Cell-Based Therapies Are Reshaping Relapsed/Refractory MCL Management Strategies
  • Aging Population and Higher Disease Prevalence Among Older Adults Expand the Addressable Market for Tolerable, Oral Therapies
  • Growth in Real-World Evidence and Biomarker Discovery Supports Personalized Treatment Planning in MCL
  • Here's How Minimal Residual Disease (MRD) Monitoring Is Emerging as a Tool for Evaluating Long-Term Remission and Therapy Response
  • Increased Availability of Orphan Drug Designation and Accelerated Approval Pathways Spurs Innovation in MCL Therapeutics
  • Here's How Combination Therapy Strategies Are Improving Progression-Free Survival While Managing Drug Resistance
  • Rising Demand for Outpatient and Home-Based Oncology Care Drives Development of Oral and Subcutaneous Formulations
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mantle Cell Lymphoma Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mantle Cell Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Laboratory Exams Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Laboratory Exams Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Laboratory Exams Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Imaging Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Imaging Tests Diagnosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Imaging Tests Diagnosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Bone Marrow Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Bone Marrow Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Bone Marrow Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Diagnosis Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Diagnosis Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Diagnosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Diagnosis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Diagnosis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals & Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospitals & Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Mantle Cell Lymphoma by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: France 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Mantle Cell Lymphoma by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: India 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Mantle Cell Lymphoma by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Mantle Cell Lymphoma by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Mantle Cell Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Mantle Cell Lymphoma Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Mantle Cell Lymphoma by Diagnosis Type - Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Mantle Cell Lymphoma by Diagnosis Type - Percentage Breakdown of Value Sales for Laboratory Exams Diagnosis, Imaging Tests Diagnosis, Bone Marrow Biopsy and Other Diagnosis Types for the Years 2014, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Mantle Cell Lymphoma by Treatment - Diagnosis Treatment and Therapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Mantle Cell Lymphoma by Treatment - Percentage Breakdown of Value Sales for Diagnosis Treatment and Therapy Treatment for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Mantle Cell Lymphoma by End-Use - Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Mantle Cell Lymphoma by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION